drugset / Trial / NCT06598462
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
Timeline
- Start
- 2024-10-16
- Primary completion
- 2027-04-30
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Solrikitug | Monoclonal antibody | — | Subcutaneous |